Judit Pich

2.4k total citations
18 papers, 667 citations indexed

About

Judit Pich is a scholar working on Virology, Infectious Diseases and Emergency Medicine. According to data from OpenAlex, Judit Pich has authored 18 papers receiving a total of 667 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Virology, 13 papers in Infectious Diseases and 8 papers in Emergency Medicine. Recurrent topics in Judit Pich's work include HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (12 papers) and HIV-related health complications and treatments (8 papers). Judit Pich is often cited by papers focused on HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (12 papers) and HIV-related health complications and treatments (8 papers). Judit Pich collaborates with scholars based in Spain, Belgium and Netherlands. Judit Pich's co-authors include José M. Gatell, Estebán Martínez, Ignacio Pérez, Félix Gutiérrez, Juan Berenguer, Josep M. Llibre, Daniel Podzamczer, Hernando Knobel, María Larrousse and Peré Domingo and has published in prestigious journals such as The Lancet, PLoS ONE and Frontiers in Immunology.

In The Last Decade

Judit Pich

18 papers receiving 649 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Judit Pich Spain 12 468 367 263 93 82 18 667
George Perez United States 15 413 0.9× 169 0.5× 143 0.5× 60 0.6× 353 4.3× 36 785
Merlin Robb United States 8 268 0.6× 261 0.7× 38 0.1× 39 0.4× 164 2.0× 11 546
Aza Rakhmanova Russia 16 789 1.7× 572 1.6× 247 0.9× 81 0.9× 332 4.0× 42 977
Sally Snyder United States 11 1.1k 2.3× 940 2.6× 349 1.3× 65 0.7× 139 1.7× 16 1.3k
Shirley Jankelevich United States 8 230 0.5× 256 0.7× 97 0.4× 74 0.8× 88 1.1× 10 560
Ermias Hailu Ethiopia 6 180 0.4× 161 0.4× 65 0.2× 16 0.2× 92 1.1× 7 418
Shannon Schrader United States 11 582 1.2× 487 1.3× 158 0.6× 27 0.3× 91 1.1× 18 700
Carlos Zala Argentina 17 693 1.5× 515 1.4× 309 1.2× 34 0.4× 176 2.1× 36 905
Maura Laverty United States 8 356 0.8× 243 0.7× 59 0.2× 53 0.6× 181 2.2× 15 517
Vincent Meiffrédy France 14 561 1.2× 526 1.4× 221 0.8× 65 0.7× 136 1.7× 24 767

Countries citing papers authored by Judit Pich

Since Specialization
Citations

This map shows the geographic impact of Judit Pich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judit Pich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judit Pich more than expected).

Fields of papers citing papers by Judit Pich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judit Pich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judit Pich. The network helps show where Judit Pich may publish in the future.

Co-authorship network of co-authors of Judit Pich

This figure shows the co-authorship network connecting the top 25 collaborators of Judit Pich. A scholar is included among the top collaborators of Judit Pich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judit Pich. Judit Pich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Leal, Lorna, Sonsoles Sánchez‐Palomino, Núria Climent, et al.. (2021). Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial. Frontiers in Immunology. 12. 767370–767370. 8 indexed citations
2.
Díaz-Brito, Vicens, Beatriz Mothe, Alberto C. Guardo, et al.. (2019). Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B. Vaccines. 7(4). 178–178. 1 indexed citations
3.
Leal, Lorna, Alberto C. Guardo, Sara Morón‐López, et al.. (2018). Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. AIDS. 32(17). 2533–2545. 75 indexed citations
4.
Guardo, Alberto C., Carmen Gómez, Vicens Díaz-Brito, et al.. (2017). Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. PLoS ONE. 12(10). e0186602–e0186602. 13 indexed citations
5.
Leal, Lorna, Agathe León, Berta Torres, et al.. (2016). A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. Journal of Antimicrobial Chemotherapy. 71(7). 1982–1986. 11 indexed citations
6.
Leal, Lorna, Agathe León, Berta Torres, et al.. (2016). A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. Journal of Antimicrobial Chemotherapy. 71(7). 1987–1993. 17 indexed citations
7.
8.
González-Cordón, Ana, Elena Ferrer, Peré Domingo, et al.. (2014). Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. HIV Medicine. 15(6). 330–338. 26 indexed citations
9.
Martínez, Estebán, et al.. (2012). Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir. AIDS Research and Human Retroviruses. 29(2). 235–241. 11 indexed citations
10.
Martínez, Estebán, Josep M. Llibre, Félix Gutiérrez, et al.. (2012). Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 26(18). 2315–2326. 106 indexed citations
11.
Pérez, Isidro Sanz, et al.. (2012). Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study. Journal of Antimicrobial Chemotherapy. 68(2). 404–408. 12 indexed citations
12.
Martínez, Estebán, Ana González-Cordón, Daniel Podzamczer, et al.. (2012). Metabolic effects of atazanavir/ritonavir vs darunavir/ritonavir in combination with tenofovir/emtricitabine in antiretroviral‐naïve patients (ATADAR Study). Journal of the International AIDS Society. 15(S4). 1–1. 3 indexed citations
13.
Martínez, Estebán, María Larrousse, Daniel Podzamczer, et al.. (2010). Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS. 24(3). F1–F9. 54 indexed citations
14.
Martínez, Estebán, María Larrousse, Josep M. Llibre, et al.. (2010). Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 24(11). 1697–1707. 141 indexed citations
15.
Martínez, Estebán, Daniel Podzamczer, Montserrat Loncà, et al.. (2010). Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study. Journal of the International AIDS Society. 13. P43–P43. 1 indexed citations
16.
Mallolas, Josep, Daniel Podzamczer, Peré Domingo, et al.. (2008). Efficacy and safety of switching from lopinavir/r to atazanavir/r in suppressed patients receiving a LPV/r-containing HAART: ATAZIP 96-week results. Journal of the International AIDS Society. 11(Suppl 1). P53–P53. 1 indexed citations
17.
Mallolas, Josep, Judit Pich, Joan Albert Arnáiz, et al.. (2007). A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients. Revista Clínica Española. 207(9). 427–432. 6 indexed citations
18.
Pich, Judit, et al.. (2003). Role of a research ethics committee in follow-up and publication of results. The Lancet. 361(9362). 1015–1016. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by George Perez Breakdown of academic impact, for papers by Merlin Robb Breakdown of academic impact, for papers by Aza Rakhmanova Breakdown of academic impact, for papers by Sally Snyder Breakdown of academic impact, for papers by Shirley Jankelevich Breakdown of academic impact, for papers by Ermias Hailu Breakdown of academic impact, for papers by Shannon Schrader Breakdown of academic impact, for papers by Carlos Zala Breakdown of academic impact, for papers by Maura Laverty Breakdown of academic impact, for papers by Vincent Meiffrédy
Rankless by CCL
2026